Note that in one AML mice model, the combination of PI3K and DNA-PK inhibitors prolonged survival of treated mice [76]; one can suggest that MRE11 should represent an alluring alternative or additional target. The gene discussed is PRKDC; the disease is acute myeloid leukemia.